Elena Sanz-Urbieta
Murcia, MU 30120, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications
Utility of tolerance assays for real-time management of infliximab infusion reactions.
Journal: Revista espanola de enfermedades digestivas
Published: January 22, 2026
Immunogenicity phenotypes and reversal of pharmacokinetic impact in anti-TNF-treated immune-mediated diseases: a real-world study.
Journal: International journal of clinical pharmacy
Published: August 10, 2025
STRATIfy-PK SCORE: A predictive tool for identifying pharmacokinetic failure risk in anti-TNF-treated patient.
Journal: British journal of clinical pharmacology
Published: July 16, 2025
Assessing early therapeutic drug monitoring of adalimumab as a predictor of treatment efficacy and immunogenicity in rheumatic diseases.
Journal: Clinical rheumatology
Published: June 26, 2025
Linezolid-induced eyelid angioedema: a case report.
Journal: European journal of hospital pharmacy : science and practice
Published: May 06, 2025
External Evaluation of Population Pharmacokinetic Models of Ustekinumab in Patients with Inflammatory Bowel Disease.
Journal: Therapeutic drug monitoring
Published: January 23, 2025
Managing refractory cytomegalovirus in an immunosuppressed patient with sarcoidosis: a case report on maribavir therapy.
Journal: European journal of hospital pharmacy : science and practice
Published: December 10, 2024
Impact of ustekinumab exposure on clinical outcomes during induction in inflammatory bowel disease.
Journal: Revista espanola de enfermedades digestivas
Published: December 04, 2024
Assessing early therapeutic drug monitoring of adalimumab as a predictor of treatment efficacy and immunogenicity in rheumatic diseases: "early therapeutic drug monitoring of adalimumab".
Journal: Clinical rheumatology
Published: November 13, 2024
Comparative evaluation of point of care assay with ELISA techniques for quantifying serum concentrations of ustekinumab in inflammatory bowel disease patients.
Journal: Gastroenterologia y hepatologia
Published: August 05, 2024
Evaluating the Accuracy and Clinical Utility of AFIAS-10 Point of Care Versus Enzyme-Linked Immunosorbent Assay in Therapeutic Drug Monitoring of Infliximab and Adalimumab.
Journal: Therapeutic drug monitoring
Published: May 22, 2024
Usefulness of population pharmacokinetics to optimize the dosage regimen of infliximab in inflammatory bowel disease patients.
Journal: Revista espanola de enfermedades digestivas
Published: July 21, 2020
Last Updated: 09/26/2026